{"id":"placebo-for-rivastigmine","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is administered in randomized controlled trials to serve as a comparator against the active drug (in this case, rivastigmine). Any observed effects are attributable to the placebo effect—psychological and physiological responses to the expectation of treatment rather than to any direct molecular action. This allows researchers to isolate the true efficacy of the active drug.","oneSentence":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:57.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in rivastigmine clinical trials (Alzheimer's disease, Parkinson's disease dementia, or Lewy body dementia)"}]},"trialDetails":[{"nctId":"NCT04226248","phase":"PHASE3","title":"CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)","status":"COMPLETED","sponsor":"University of Bristol","startDate":"2020-01-02","conditions":"Parkinson Disease","enrollment":600},{"nctId":"NCT06382649","phase":"PHASE2","title":"Rivastigmine for Antimuscarinic Delirium","status":"SUSPENDED","sponsor":"Washington University School of Medicine","startDate":"2026-11","conditions":"Anticholinergic Toxicity","enrollment":42},{"nctId":"NCT06399679","phase":"PHASE2","title":"Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-11-04","conditions":"Anticholinergic Toxicity","enrollment":42},{"nctId":"NCT04366518","phase":"EARLY_PHASE1","title":"Toward a Computationally-Informed, Personalized Treatment for Hallucinations","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-07-15","conditions":"Hallucinations, Auditory, Psychosis","enrollment":35},{"nctId":"NCT06702124","phase":"PHASE3","title":"A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease","status":"RECRUITING","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2023-12-01","conditions":"Alzheimer Disease","enrollment":348},{"nctId":"NCT06537076","phase":"PHASE2","title":"Safety and Efficacy of AR1005 in Patients with Lewy Body Disease","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-01-01","conditions":"Lewy Body Dementia","enrollment":60},{"nctId":"NCT03454646","phase":"PHASE4","title":"Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2024-06-01","conditions":"Alzheimer Disease, Cholinesterase Inhibitors","enrollment":1205},{"nctId":"NCT01340885","phase":"PHASE4","title":"Cognitive Decline in Non-demented PD","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2011-01","conditions":"Parkinson's Disease","enrollment":9},{"nctId":"NCT01856738","phase":"PHASE4","title":"Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-11","conditions":"Parkinson's Disease","enrollment":91},{"nctId":"NCT01852110","phase":"PHASE2","title":"Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-22","conditions":"Alzheimer's Disease","enrollment":240},{"nctId":"NCT01677754","phase":"PHASE2","title":"A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-10-24","conditions":"Alzheimer's Disease","enrollment":542},{"nctId":"NCT02035982","phase":"PHASE3","title":"Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2010-07","conditions":"Alzheimer's Disease, Dementia","enrollment":40},{"nctId":"NCT01519271","phase":"PHASE4","title":"Mild Cognitive Impairment in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-12","conditions":"Parkinson's Disease, Mild Cognitive Impairment","enrollment":28},{"nctId":"NCT01602198","phase":"NA","title":"Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2011-06","conditions":"Mild Cognitive Disorder, Mild Cognitive Impairment","enrollment":1},{"nctId":"NCT00158210","phase":"PHASE1","title":"Rivastigmine For Methamphetamine Dependent Individuals","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2006-05","conditions":"Substance-Related Disorders","enrollment":18},{"nctId":"NCT01084135","phase":"PHASE1, PHASE2","title":"Rivastigmine Study in Adolescents With Down Syndrome","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-11","conditions":"Down Syndrome","enrollment":42},{"nctId":"NCT00835159","phase":"PHASE4","title":"Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2008-12","conditions":"Delirium, Postoperative Cognitive Dysfunction","enrollment":30},{"nctId":"NCT01030692","phase":"PHASE1","title":"Rivastigmine and Huperzine A as Treatments for Cocaine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-01","conditions":"Cocaine Dependence, Cocaine Addiction, Cocaine Abuse","enrollment":72},{"nctId":"NCT00423085","phase":"PHASE3","title":"Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Alzheimer's Disease","enrollment":859},{"nctId":"NCT00948766","phase":"PHASE4","title":"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Alzheimer's Disease","enrollment":716},{"nctId":"NCT00506415","phase":"PHASE3","title":"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-06","conditions":"Alzheimer Disease","enrollment":1584},{"nctId":"NCT01073319","phase":"PHASE1","title":"Rivastigmine as a Treatment for Methamphetamine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse","enrollment":17},{"nctId":"NCT00766363","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"FORUM Pharmaceuticals Inc","startDate":"2008-10","conditions":"Alzheimer's Disease, Central Nervous System Diseases","enrollment":49},{"nctId":"NCT00704301","phase":"PHASE4","title":"Rivastigmine for Intensive Care Unit (ICU) Delirium","status":"TERMINATED","sponsor":"UMC Utrecht","startDate":"2008-11","conditions":"Delirium","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":345,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"marketed","status":"active","brandName":"Placebo (for rivastigmine)","genericName":"Placebo (for rivastigmine)","companyName":"Amsterdam UMC, location VUmc","companyId":"amsterdam-umc-location-vumc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials. Used for Control arm in rivastigmine clinical trials (Alzheimer's disease, Parkinson's disease dementia, or Lewy body dementia).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}